AR069860A1 - Metodo para purificar un anticuerpo cd20 - Google Patents

Metodo para purificar un anticuerpo cd20

Info

Publication number
AR069860A1
AR069860A1 ARP080105605A ARP080105605A AR069860A1 AR 069860 A1 AR069860 A1 AR 069860A1 AR P080105605 A ARP080105605 A AR P080105605A AR P080105605 A ARP080105605 A AR P080105605A AR 069860 A1 AR069860 A1 AR 069860A1
Authority
AR
Argentina
Prior art keywords
antibody
purifying
mixture
hccf
recovering
Prior art date
Application number
ARP080105605A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR069860A1 publication Critical patent/AR069860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La mezcla consistiendo en un fluido celular cosechado concentrado (HCCF) de un cultivo celular recombinante que produce el anticuerpo CD20, no ha sido sometida a liofilizacion previa. También se proveen cristales de un anticuerpo CD20, una composicion farmacéutica y un método de tratamiento de una enfermedad o afeccion asociada a CD20. Reivindicacion 1: Un método para purificar un anticuerpo CD20 de una mezcla, caracterizado porque comprende cristalizar el anticuerpo CD20 y recuperar el anticuerpo CD20 de la mezcla.
ARP080105605A 2007-12-21 2008-12-19 Metodo para purificar un anticuerpo cd20 AR069860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1628807P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
AR069860A1 true AR069860A1 (es) 2010-02-24

Family

ID=40347971

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105605A AR069860A1 (es) 2007-12-21 2008-12-19 Metodo para purificar un anticuerpo cd20

Country Status (15)

Country Link
US (1) US20110020322A1 (es)
EP (1) EP2235056A1 (es)
JP (1) JP2011507870A (es)
KR (1) KR20100105720A (es)
CN (1) CN101945890A (es)
AR (1) AR069860A1 (es)
AU (1) AU2008343347A1 (es)
BR (1) BRPI0820604A2 (es)
CA (1) CA2708951A1 (es)
CL (1) CL2008003790A1 (es)
IL (1) IL206227A0 (es)
PE (1) PE20091337A1 (es)
RU (1) RU2010130467A (es)
TW (1) TW200932758A (es)
WO (1) WO2009085765A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544865C (en) 2003-11-05 2019-07-09 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CN101577344B (zh) * 2009-06-11 2011-04-20 珠海银通交通能源投资有限公司 动力电池
KR101844859B1 (ko) 2009-08-06 2018-05-18 제넨테크, 인크. 단백질 정제 시의 바이러스 제거의 개선방법
IN2014DN09097A (es) * 2012-05-11 2015-05-22 Novartis Ag
EP2864346B1 (en) * 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Method of purifying an antibody
US10293106B2 (en) * 2013-04-03 2019-05-21 Becton, Dickinson And Company Intravenous tubing set modified for in-line catheter flushing
KR101569783B1 (ko) 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
EP3541843A1 (en) 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
IT202100004496A1 (it) 2021-02-25 2022-08-25 Univ Della Calabria Recupero di farmaci biologici o loro frammenti da soluzioni impure mediante cristallizzazione o precipitazione con membrane

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5509070A (en) * 1992-12-15 1996-04-16 Softlock Services Inc. Method for encouraging purchase of executable and non-executable software
US6134659A (en) * 1998-01-07 2000-10-17 Sprong; Katherine A. Controlled usage software
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)

Also Published As

Publication number Publication date
PE20091337A1 (es) 2009-09-03
KR20100105720A (ko) 2010-09-29
CN101945890A (zh) 2011-01-12
CL2008003790A1 (es) 2010-02-05
TW200932758A (en) 2009-08-01
EP2235056A1 (en) 2010-10-06
WO2009085765A1 (en) 2009-07-09
CA2708951A1 (en) 2009-07-09
US20110020322A1 (en) 2011-01-27
RU2010130467A (ru) 2012-01-27
JP2011507870A (ja) 2011-03-10
BRPI0820604A2 (pt) 2017-05-09
AU2008343347A1 (en) 2009-07-09
IL206227A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
AR069860A1 (es) Metodo para purificar un anticuerpo cd20
ES2542853T3 (es) Método para tratar miastenia grave
ES2533874T3 (es) Armazón proteico
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
BR112012012460A8 (pt) método de liofilização, composições e kits
CL2018000238A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
CL2011000206A1 (es) Composicion biocida que comprende ciprodinil y fluazinam; metodo para controlar enfermedades, en plantas utiles o en material de propagacion, causadas por fitopatogenos (div. sol. n°2602-06).
ECSP109956A (es) Composiciones y métodos para controlar nemátodos
AR111813A2 (es) Compuestos y composiciones para el control de nematodos
PE20130588A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BRPI0516323A (pt) construtos de rna
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR048411A1 (es) Metodos para controlar patogenos de plantas que utilizan n-fosfonometilglicina
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
PE20091109A1 (es) Anticuerpo humanizado contra la proteina e2 del virus de la hepatitis c
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
AR063899A1 (es) Materiales plasticos
WO2006059247A8 (en) VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC
WO2014049447A3 (en) A whole, leech saliva extract
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
MX2018008845A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure